Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Sep 6;9(9):CD009422.
doi: 10.1002/14651858.CD009422.pub4.

Vitamin E supplementation in people with cystic fibrosis

Peter O Okebukola  1 , Sonal Kansra  2 , Joanne Barrett  3
Affiliations
Meta-Analysis

Vitamin E supplementation in people with cystic fibrosis

Peter O Okebukola et al. Cochrane Database Syst Rev. .

Abstract

Background: People with cystic fibrosis are at an increased risk of fat-soluble vitamin deficiency, including vitamin E. Vitamin E deficiency can cause a host of conditions such as haemolytic anaemia, cerebellar ataxia and cognitive difficulties. Vitamin E supplementation is widely recommended for people with cystic fibrosis and aims to ameliorate this deficiency. This is an updated version of the review.

Objectives: To determine the effects of any level of vitamin E supplementation on the frequency of vitamin E deficiency disorders in people with cystic fibrosis.

Search methods: We searched the Cochrane Group's Cystic Fibrosis Trials Register and also searched international online trial registries for any ongoing clinical trials that were not identified during our register search. Date of last search of the Register: 11 August 2020. Date of last search of international online trial registries: 20 July 2020.

Selection criteria: Randomised controlled trials and quasi-randomised controlled trials comparing any preparation of vitamin E supplementation to placebo or no supplement, regardless of dosage or duration.

Data collection and analysis: Two authors extracted outcome data from each study (published information) and assessed the risk of bias of each included study. They assessed the quality of the evidence using GRADE.

Main results: Four studies with a total of 141 participants were included in the review, two of these were in children (aged six months to 14.5 years), and two did not specify participants' age. All studies used different formulations and doses of vitamin E for various durations of treatment (10 days to six months). Two studies compared the supplementation of fat-soluble as well as water-soluble formulations to no supplementation in different arms of the same study. A third study compared a water-soluble formulation to a placebo; and in the fourth study a fat-soluble formulation of vitamin E was assessed against placebo. There was limited detail about randomisation and blinding in the included studies which compromises the quality of the evidence base for the review. The heterogeneous mix of the formulations with differing biovailabilities among these studies also limits the generalisability of the data to the wider cystic fibrosis population. None of the studies in either comparison report the review's primary outcomes of vitamin E total lipid ratio or the incidence of vitamin E-specific deficiency disorders, or the secondary outcomes lung function or quality of life. Water-soluble vitamin E Water-soluble vitamin E may improve serum vitamin E levels compared with control at six months, one study (45 participants), mean difference (MD) 19.74 umol/L (95% confidence interval (CI) 13.48 to 26.00) (low-quality evidence). Similar results were also seen at one month, two studies (32 participants), MD 17.66 umol/L (95% CI 10.59 to 24.74) and at three months, one study (45 participants), MD 11.61 umol/L (95% CI 4.77 to 18.45). Only one study (45 participants) reported weight (secondary outcome of growth and nutritional status) at one and six months, but showed no difference between treatment and control at either time point. Fat-soluble vitamin E Two studies (36 participants) reported higher levels of serum vitamin E at one month with fat-soluble vitamin E compared with control, MD 13.59 umol/L (95% CI 9.52 to 17.66); however, at three months one study (36 participants) showed no difference between treatment and control. No studies in this comparison reported on growth or nutritional status.

Authors' conclusions: Vitamin E supplementation may lead to an improvement in vitamin E levels in people with cystic fibrosis, although evidence we assessed was low quality. No data on other outcomes of interest were available to allow conclusions about any other benefits of this therapy. In future, larger studies are needed, especially in people already being treated with enteric-coated pancreatic enzymes and supplemented with vitamin E, to look at more specific outcome measures such as vitamin E status, lung function and nutritional status. Future studies could also look at the optimal dose of vitamin E required to achieve maximal clinical effectiveness.

PubMed Disclaimer

Conflict of interest statement

All authors: none known.

Figures

1
1
Study flow diagram
1.1
1.1. Analysis
Comparison 1: Water‐miscible vitamin E supplementation versus control, Outcome 1: Serum vitamin E levels
1.2
1.2. Analysis
Comparison 1: Water‐miscible vitamin E supplementation versus control, Outcome 2: Weight
2.1
2.1. Analysis
Comparison 2: Fat‐soluble vitamin E supplementation versus control, Outcome 1: Serum vitamin E levels
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Harries 1969 {published data only}
    1. Harries JT, Muller DP. Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood 1971;46(247):341-4. [CFGD REGISTER: GN49b] - PMC - PubMed
    1. Harries JT, Muller DPR. Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis. In: 5th International Cystic Fibrosis Conference; 1969 Sept. 22-26; Cambridge, England. 1969:298-307. [CFGD REGISTER: GN49]
Keljo 2000 {published and unpublished data}
    1. Kelijo DJ, Giroir B, Jialal I. Circulating tumor necrosis factor-alpha and IL-6 levels in patients with cystic fibrosis and mild lung disease: effects of dnase and alpa-tocopherol therapy [personal communication]. Unpublished article 15 January 2014. [CFGD REGISTER: GN87b]
    1. Keljo DJ, Giroir B, Jialal I. Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology 2000;30 Suppl 20:326. [CFGD REGISTER: GN87]
Levin 1961 {published data only}
    1. Levin S, Gordon MH, Nitowsky HM, Goldman C, di Sant'Agnese P, Gordon HH. Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics 1961;27:578-88. [CFGD REGISTER: GN73b] [DOI: 10.1136/adc.49.3.247-a] [MEDLINE: ] - DOI - PubMed
    1. Levin S. Muscular performance and vitamin E in cystic fibrosis [letter]. Archives of Disease in Childhood 1974;49(3):247. [CFGD REGISTER: GN73a] [MEDLINE: ] - PMC - PubMed
Wong 1988 {published data only}
    1. Wong LTK, Halstead C, Davidson AGF, Fang PM. Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology 1988;5 Suppl 2:144. [CFGD REGISTER: GN52]

References to studies excluded from this review

Homola 2017 {published data only}
    1. Homola L, Holcikova A, Pokojova E, Tomandl J, Mala M. Prospective randomized open label comparison of fat soluble and water soluble vitamin supplementation in children with CF. Journal of Cystic Fibrosis 2017;16(Suppl 1):S141. [CFGD REGISTER: GN273a]
Jacquemin 2009 {published data only}
    1. Jacquemin E, Hermeziu B, Kibleur Y, Friteau I, Mathieu D, Le Coz F, et al. Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis. Journal of Clinical Pharmacy and Therapeutics 2009;34(5):515-22. [CFGD REGISTER: GN216] [MEDLINE: ] - PubMed
Kerem 2009 {published data only}
    1. NCT00889434. Efficacy and safety study of EGCG/Tocotrienol in 18 patients with splicing-mutation-mediated cystic fibrosis (CF). http://clinicaltrials.gov/show/NCT00889434 (accessed 10 March 2012). [CLINICALTRIALS.GOV: NCT00889434]
Munck 2010 {published data only}
    1. Munck A, Ginies JL, Huet F, Wizla N, Gerardin M, Darviot E, et al. A new water-soluble oral vitamin E formulation in cystic fibrosis (CF) children [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S91, Abstract no: 352. [CFGD REGISTER: GN219] [MEDLINE: ]
Nasr 1993 {published data only}
    1. Nasr SZ, O'Leary MH, Hillermeier C. Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis. Journal of Pediatrics 1993;122(5 Pt 1):810-2. [CFGD REGISTER: GN42] - PubMed
Papas 2007 {published data only}
    1. Papas K, Kalbfleisch J, Mohon R. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Digestive Diseases and Sciences 2007;52(2):347-52. [CFGD REGISTER: GN114] [MEDLINE: ] - PubMed
Sagel 2011 {published data only}
    1. Sagel SD, Sontag MK, Anthony MM, Emmett P, Papas KA. Safety and efficacy of an antioxidant-rich multivitamin supplement in cystic fibrosis. Journal of Cystic Fibrosis 2011;10(1):31-6. [CLINCALTRIALS.GOV: NCT01018303] - PubMed
Thomas 1995 {published data only}
    1. Thomas PS, Bellamy M, Geddes D. Malabsorption of vitamin E in cystic fibrosis improved after ursodeoxycholic acid [letter]. Lancet 1995;346(8984):1230-1. [CFGD REGISTER: GN77] [MEDLINE: ] - PubMed
Winklhofer‐Roob 1992 {published data only}
    1. Winklhofer-Roob BM, Shmerling DH, Schimek MG. Response of vitamin E deficient patients with cystic fibrosis (CF) to oral RRR-alpha-tocopherol or all-rac-alpha-tocopheryl acetate [abstract]. Clinical Nutrition 1992;11 Suppl:67. [CFGD REGISTER: GN48b]
Winklhofer‐Roob 1996 {published data only}
    1. Winklhofer Roob BM, van't Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. American Journal of Clinical Nutrition 1996;63(5):722-8. [CFGD REGISTER: GN48a] [MEDLINE: ] - PubMed
Wood 2003 {published data only}
    1. Wood LG, Fitzgerald DA, Lee AK, Garg ML. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. American Journal of Clinical Nutrition 2003;77(1):150-9. [CFGD REGISTER: GN98] - PubMed

References to ongoing studies

EUCTR2007‐001007‐38‐FR {published data only}
    1. STUDY OF THE LONG TERM BIOLOGICAL EFFICACY AND TOLERABILITY OF VEDROP (VITAMIN E-TPGS FORMULATION) AFTER DAILY ORAL ADMINISTRATION IN 30 PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS - 1ORP2. Ongoing study. 25/04/2007. Contact author for more information.

Additional references

Aaron 2004
    1. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. American Journal of Respiratory and Critical Care Medicine 2004;169:811-5. - PubMed
Aparicio 2001
    1. Aparicio JM, Belanger-Quintana A, Suarez L. Ataxia with isolated vitamin E deficiency: case report and review of the literature. Journal of Pediatric Gastroenterology and Nutrition 2001;33(2):206-10. - PubMed
Bell 2002
    1. Bell SC, Shepherd RW. Optimising nutrition in cystic fibrosis. Journal of Cystic Fibrosis 2002;1(2):47-50. [DOI: 10.1016/S1569-1993(02)00031-0] - DOI - PubMed
Biesalski 2009
    1. Biesalski HK. Vitamin E requirements in parenteral nutrition. Gastroenterology 2009;137(5):S92-S104. [DOI: 10.1053/j.gastro.2009.07.073] - DOI - PubMed
Bines 2005
    1. Bines JE, Truby HD, Armstrong DS, Carzino R, Grimwood R. Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. Journal of Paediatrics and Child Health 2005;41:663-8. - PubMed
Brigelius‐Flohé 2009
    1. Brigelius-Flohé R. Vitamin E: The Shrew Waiting to be Tamed. Free Radical Biology & Medicine 2009;46:543–54. - PubMed
Ciofu 2019
    1. Ciofu O, Lykkesfeldt J. Antioxidant supplementation for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2019, Issue 10. Art. No: CD007020. [DOI: 10.1002/14651858.CD007020.pub4] - DOI - PMC - PubMed
Cynamon 1988
    1. Cynamon HA, Milov DE, Valenstein E, Wagner M. Effects of vitamin E deficiency on neurologic function in patients with cystic fibrosis. Pediatrics 1988;113:637-9. - PubMed
Dodge 2006
    1. Dodge JA, Turck D. Cystic fibrosis: nutritional consequences and management. Best Practice & Research. Clinical Gastroenterology 2006;20(3):531-46. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Farrell 2008
    1. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. Journal of Pediatrics 2008;153(2):S4-S14. - PMC - PubMed
Gee 2000
    1. Gee L, Abbott J, Conway S, Etherington C, Webb A. Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis. Thorax 2000;55(11):946-54. - PMC - PubMed
Goss 2004
    1. Goss CH, Rosenfeld M. Update on cystic fibrosis epidemiology. Current Opinion in Pulmonary Medicine 2004;10(6):510-4. - PubMed
Hakim 2007
    1. Hakim F, Kerem E, Rivlin J, Bentur L, Stankiewicz H, Bdolach-Abram T, et al. Vitamins A and E and pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2007;45(3):347-53. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2011a
    1. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ, Altman DG on behalf of the Cochrane Statistical Methods Group, editor(s). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.
Higgins 2011c
    1. Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group, editor(s). Chapter 9: Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from cochrane-handbook.org.
Kerem 2005
    1. Kerem E, Conway S, Elborn S, Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 2005;4:7-26. - PubMed
Koscik 2005
    1. Koscik RL, Lai HJ, Laxova A, Zaremba KM, Kosorok MR, Douglas JA, et al. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. Journal of Pediatrics 2005;147(3 Suppl):S51-S56. - PubMed
Kozlowska 2008
    1. Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, et al. Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2008;178(1):42-9. - PubMed
Linnane 2008
    1. Linnane BM, Hall GL, Nolan G, Brennan S, Stick SM, Sly PD, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. American Journal of Respiratory and Critical Care Medicine 2008;178(12):1238-44. - PubMed
Mayo Clinic 2009
    1. Mayo Clinic. Vitamin E (oral route). www.mayoclinic.com/health/drug-information/DR601967/FLUSHCACHE=0&UPDATEA... (accessed 01 March 2011).
Peters 1996
    1. Peters SA, Kelly FJ. Vitamin E supplementation in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1996;22:341-5. - PubMed
Quittner 2009
    1. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8. - PMC - PubMed
RevMan 2011 [Computer program]
    1. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Sinaasappel 2002
    1. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkampd G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of Cystic Fibrosis 2002;1(2):51-75. [PMID: ] - PubMed
Suskind 2009
    1. Suskind DL. Nutritional Deficiencies During Normal Growth. Pediatric Clinics of North America 2009;56(5):1035-53. - PubMed
Swann 1998
    1. Swann IL, Kendra JR. Anaemia, vitamin E deficiency and failure to thrive in an infant. Clinical and Laboratory Haematology 1998;20(1):61-3. - PubMed
Taylor 2010
    1. Taylor C, Connolly S. Gastrointestinal disease and nutrition. In: Horsley A, Cunningham S, Innes JA, editors(s). Cystic Fibrosis. Oxford: Oxford University Press, 2010:81-93.
Thurnham 1986
    1. Thurnham DI, Davies JA, Crump BJ, Situnayake RD, Davis M. The use of different lipids to express serum tocopherol: lipid ratios for the measurement of vitamin E status. Annals of Clinical Biochemistry 1986;23(Pt 5):514-20. - PubMed
Ueda 2009
    1. Ueda N, Suzuki Y, Rino Y, Takahashi T, Imada T, Takanashi Y, et al. Correlation between neurological dysfunction with vitamin E deficiency and gastrectomy. Journal of the Neurological Sciences 2009;287:216-20. [DOI: 10.1016/j.jns.2009.07.020] - DOI - PubMed
UK Cystic Fibrosis Trust 2002
    1. UK Cystic Fibrosis Trust Nutrition Working Group. Nutritional Management of Cystic Fibrosis. UK Cystic Fibrosis Trust, April 2002. [ISBN 0-9540536-5-6]
Welsh 2001
    1. Welsh M, Ramsey B, Accurso F, Cutting G. Cystic Fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors(s). The Metabolic and Molecular Basis of Inherited Disease. 8th edition. New York: McGraw-Hill, 2001:5121-88.
Wilfond 1994
    1. Wilfond BS, Farrell PM, Laxova A, Mischler E. Severe hemolytic anemia associated with vitamin E deficiency in infants with cystic fibrosis. Implications for neonatal screening. Clinica Pediatrica 1994;33(1):2-7. - PubMed
Winbauer 1999
    1. Winbauer AN, Pingree SS, Nuttall KL. Evaluating serum alpha-tocopherol (vitamin E) in terms of a lipid ratio. Annals Clinical and Laboratory Science 1999;29(3):185-91. - PubMed

References to other published versions of this review

Okebukola 2011
    1. Okebukola PO, Kansra S, McCabe H. Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No: CD009422. [DOI: 10.1002/14651858.CD009422] - DOI
Okebukola 2014
    1. Okebukola PO, Kansra S, Barrett J. Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 12. Art. No: CD009422. [DOI: 10.1002/14651858.CD009422.pub2] - DOI - PubMed
Okebukola 2017
    1. Okebukola PO, Kansra S, Barrett J. Vitamin E supplementation in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 3. Art. No: CD009422. [DOI: 10.1002/14651858.CD009422.pub3] - DOI - PMC - PubMed

Publication types

MeSH terms